JHL Biotech, a Hsinchu, Taiwan-based contract manufacturing organization, has formed a manufacturing services partnership with Aslan Pharmaceuticals, a Singapore-based biotechnology company focused on immunotherapies and targeted agents for Asia-prevalent tumor types, to provide process development services to Aslan for the continued development of Aslan’s ASLAN004 monoclonal antibody (mAb) program. ASLAN004 is a fully human mAb that blocks the signaling of the interleukin-4 and interleukin-13 receptors.

Under the partnership, Aslan will work with JHL to perform process development and manufacturing of ASLAN004, including analytics and process development to manufacture the mAb for clinical trials. Development and manufacturing of ASLAN004 will commence in 2016 and will be undertaken at JHL Biotech’s GMP-certified facility in Zhubei, Taiwan.

Source: JHL Biotech and Aslan Pharmaceuticals